Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

PG&E Q2 EPS $0.25 Misses $0.28 Estimate

-Reuters
byMichael Horton
July 28, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

-Reuters

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Ocular Therapeutix Announced Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD; Said 80% of Subjects were Rescue-Free up to 6 months and 73% of Subjects Were Rescue-Free up to 7 months Following a Single OTX-…

By Charles Gross
September 27, 6:02 AM
Ocular Therapeutix, Inc. (NASDAQ: OCUL) today announced interim 7-month data from its U.S. Phase 1 clinical trial evaluating OTX-TKI, the Company's axitinib intravitreal hydrogel implant being developed for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases.

OCUL